Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma

benzinga.com/news/fda/25/07/46244666/regenerons-lynozyfic-gains-accelerated-fda-approval-for-heavily-pre-treated-multiple-myeloma

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) Lynozyfic (linvoseltamab-gcpt) for adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of…

This story appeared on benzinga.com, 2025-07-03 13:37:41.
The Entire Business World on a Single Page. Free to Use →